tiludronate-disodium

Description: Tiludronate (Tiludronate disodium; Tiludronic Acid disodium) is a novel and potent bisphosphonate agent which prevents postmenopausal bone loss and is used for treatment of Paget's disease of bone (osteitis deformans) in human medicine. In veterinary medicine, tiludronic acid is used to treat navicular disease and bone spavin in horses. Its trade names are Tildren and Equidronate. It is approved for treatment of navicular disease and distal tarsal osteoarthritis in Europe, and was approved for treatment of navicular disease in the United States in 2014. Tiludronate is a non-nitrogenous bisphosphonate that inhibits osteoclasts, the primary cell responsible for the breakdown of bone required for bone remodeling.

References:

1. Reginster JY, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989 Dec 23-30; 2(8678-8679):1469-71.

2. NunesNLT, et al. Effects of local administration of tiludronic acid onexperimental periodontitis in diabetic rats. J Periodontol. 2018Jan; 89(1):105-116.

3. Licence variations regarding tiludronate disodium. Vet Rec. 2015 Oct 24; 177(16):423-4. doi: 10.1136/vr.h5621. PubMed PMID: 26494897.

Related CAS #: 114084-78-5 (free acid) 149845-07-8 (sodium) 138926-19-9 (sodium hydrate)